Skip to main content
PMC home page
Heart logoLink to Heart
. 1997 Jan;77(1):13–17. doi: 10.1136/hrt.77.1.13

Antithrombotic treatment in stable coronary syndromes: long-term intermittent urokinase therapy in end-stage coronary artery disease and refractory angina pectoris.

F C Schoebel 1, T W Jax 1, Y Fischer 1, B E Strauer 1, M Leschke 1
PMCID: PMC484628  PMID: 9038688

Abstract

Interventions that modify lipid metabolism and blood coagulation have been shown to favourably influence the natural course of coronary artery disease in terms of the primary prevention and treatment of acute cardiovascular events. Various findings suggest that such interventions may also preserve and enhance myocardial perfusion in the chronic stage of the disease. Long-term intermittent urokinase therapy was developed for patients with end-stage coronary artery disease and refractory angina pectoris. A dose of 500,000 IU of urokinase given intravenously as a bolus three times a week for of 12 weeks reduced symptoms by 70% and was accompanied by objective improvements in myocardial perfusion and an increase of ergometric exercise capacity. The possible therapeutic mechanisms of long-term intermittent urokinase therapy-improvement of rheological blood properties mediated by fibrinogen reduction, thrombolysis of non-occlusive subclinical thrombi, and regression of atherosclerotic plaques-are discussed in the context of other antithrombotic approaches.

Full text

PDF
13

Images in this article

15Image
on p.15

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson T. J., Meredith I. T., Yeung A. C., Frei B., Selwyn A. P., Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med. 1995 Feb 23;332(8):488–493. doi: 10.1056/NEJM199502233320802. [DOI] [PubMed] [Google Scholar]
  2. Bini A., Fenoglio J. J., Jr, Mesa-Tejada R., Kudryk B., Kaplan K. L. Identification and distribution of fibrinogen, fibrin, and fibrin(ogen) degradation products in atherosclerosis. Use of monoclonal antibodies. Arteriosclerosis. 1989 Jan-Feb;9(1):109–121. doi: 10.1161/01.atv.9.1.109. [DOI] [PubMed] [Google Scholar]
  3. Broadhurst P., Kelleher C., Hughes L., Imeson J. D., Raftery E. B. Fibrinogen, factor VII clotting activity and coronary artery disease severity. Atherosclerosis. 1990 Dec;85(2-3):169–173. doi: 10.1016/0021-9150(90)90108-u. [DOI] [PubMed] [Google Scholar]
  4. Campeau L. Letter: Grading of angina pectoris. Circulation. 1976 Sep;54(3):522–523. [PubMed] [Google Scholar]
  5. Ceriello A., Pirisi M., Giacomello R., Stel G., Falleti E., Motz E., Lizzio S., Gonano F., Bartoli E. Fibrinogen plasma levels as a marker of thrombin activation: new insights on the role of fibrinogen as a cardiovascular risk factor. Thromb Haemost. 1994 May;71(5):593–595. [PubMed] [Google Scholar]
  6. Davies M. J., Bland J. M., Hangartner J. R., Angelini A., Thomas A. C. Factors influencing the presence or absence of acute coronary artery thrombi in sudden ischaemic death. Eur Heart J. 1989 Mar;10(3):203–208. doi: 10.1093/oxfordjournals.eurheartj.a059467. [DOI] [PubMed] [Google Scholar]
  7. Davies M. J., Thomas A. C., Knapman P. A., Hangartner J. R. Intramyocardial platelet aggregation in patients with unstable angina suffering sudden ischemic cardiac death. Circulation. 1986 Mar;73(3):418–427. doi: 10.1161/01.cir.73.3.418. [DOI] [PubMed] [Google Scholar]
  8. Di Salvo T. G., Fuster V. Antithrombotic therapy in coronary artery disease. Curr Opin Lipidol. 1994 Aug;5(4):290–304. doi: 10.1097/00041433-199408000-00007. [DOI] [PubMed] [Google Scholar]
  9. Egashira K., Hirooka Y., Kai H., Sugimachi M., Suzuki S., Inou T., Takeshita A. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation. 1994 Jun;89(6):2519–2524. doi: 10.1161/01.cir.89.6.2519. [DOI] [PubMed] [Google Scholar]
  10. Ericsson C. G., Hamsten A., Nilsson J., Grip L., Svane B., de Faire U. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet. 1996 Mar 30;347(9005):849–853. doi: 10.1016/s0140-6736(96)91343-4. [DOI] [PubMed] [Google Scholar]
  11. Ernst E., Resch K. L. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med. 1993 Jun 15;118(12):956–963. doi: 10.7326/0003-4819-118-12-199306150-00008. [DOI] [PubMed] [Google Scholar]
  12. Falk E. Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death. Autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion. Circulation. 1985 Apr;71(4):699–708. doi: 10.1161/01.cir.71.4.699. [DOI] [PubMed] [Google Scholar]
  13. Fuster V., Badimon L., Badimon J. J., Chesebro J. H. The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N Engl J Med. 1992 Jan 23;326(4):242–250. doi: 10.1056/NEJM199201233260406. [DOI] [PubMed] [Google Scholar]
  14. Fuster V., Badimon L., Badimon J. J., Chesebro J. H. The pathogenesis of coronary artery disease and the acute coronary syndromes (2). N Engl J Med. 1992 Jan 30;326(5):310–318. doi: 10.1056/NEJM199201303260506. [DOI] [PubMed] [Google Scholar]
  15. Gordon R. J., Snyder G. K., Tritel H., Taylor W. J. Potential significance of plasma viscosity and hematocrit variations in myocardial ischemia. Am Heart J. 1974 Feb;87(2):175–182. doi: 10.1016/0002-8703(74)90038-6. [DOI] [PubMed] [Google Scholar]
  16. Gotto A. M., Jr Lipid lowering, regression, and coronary events. A review of the Interdisciplinary Council on Lipids and Cardiovascular Risk Intervention, Seventh Council meeting. Circulation. 1995 Aug 1;92(3):646–656. doi: 10.1161/01.cir.92.3.646. [DOI] [PubMed] [Google Scholar]
  17. Gould K. L., Martucci J. P., Goldberg D. I., Hess M. J., Edens R. P., Latifi R., Dudrick S. J. Short-term cholesterol lowering decreases size and severity of perfusion abnormalities by positron emission tomography after dipyridamole in patients with coronary artery disease. A potential noninvasive marker of healing coronary endothelium. Circulation. 1994 Apr;89(4):1530–1538. doi: 10.1161/01.cir.89.4.1530. [DOI] [PubMed] [Google Scholar]
  18. Gurewich V., Lipinski B., Hyde E. The effect of the fibrinogen concentration and the leukocyte count on intravascular fibrin deposition from soluble fibrin monomer complexes. Thromb Haemost. 1976 Dec 31;36(3):605–614. [PubMed] [Google Scholar]
  19. Itoh A., Miyazaki S., Nonogi H., Daikoku S., Haze K. Angioscopic prediction of successful dilatation and of restenosis in percutaneous transluminal coronary angioplasty. Significance of yellow plaque. Circulation. 1995 Mar 1;91(5):1389–1396. doi: 10.1161/01.cir.91.5.1389. [DOI] [PubMed] [Google Scholar]
  20. Jan K. M., Chien S., Bigger J. T., Jr Observations on blood viscosity changes after acute myocardial infarction. Circulation. 1975 Jun;51(6):1079–1084. doi: 10.1161/01.cir.51.6.1079. [DOI] [PubMed] [Google Scholar]
  21. Koenig W., Ernst E. The possible role of hemorheology in atherothrombogenesis. Atherosclerosis. 1992 Jun;94(2-3):93–107. doi: 10.1016/0021-9150(92)90234-8. [DOI] [PubMed] [Google Scholar]
  22. Lenfant C. NHLBI funding policies. Enhancing stability, predictability, and cost control. Circulation. 1994 Jul;90(1):1–1. doi: 10.1161/01.cir.90.1.1. [DOI] [PubMed] [Google Scholar]
  23. Leschke M., Blanke H., Stellwaag M., Motz W., Strauer B. E. Hyperfibrinogenämie und pathologische Plasmaviskosität. Pathogenetische Faktoren bei der instabilen Angina pectoris? Dtsch Med Wochenschr. 1988 Jul 29;113(30):1175–1181. doi: 10.1055/s-2008-1067789. [DOI] [PubMed] [Google Scholar]
  24. Leschke M., Höffken H., Motz W., Blanke H., Schöbel F., Strauer B. E. Chronisch-intermittierende Urokinasetherapie bei therapierefraktärer Angina pectoris. Dtsch Med Wochenschr. 1992 Jan 17;117(3):81–87. doi: 10.1055/s-2008-1062283. [DOI] [PubMed] [Google Scholar]
  25. Leschke M., Schoebel F. C., Mecklenbeck W., Stein D., Jax T. W., Müller-Gärtner H. W., Strauer B. E. Long-term intermittent urokinase therapy in patients with end-stage coronary artery disease and refractory angina pectoris: a randomized dose-response trial. J Am Coll Cardiol. 1996 Mar 1;27(3):575–584. doi: 10.1016/0735-1097(95)00494-7. [DOI] [PubMed] [Google Scholar]
  26. Leung W. H., Lau C. P., Wong C. K. Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolaemic patients. Lancet. 1993 Jun 12;341(8859):1496–1500. doi: 10.1016/0140-6736(93)90634-s. [DOI] [PubMed] [Google Scholar]
  27. Melandri G., Semprini F., Cervi V., Candiotti N., Palazzini E., Branzi A., Magnani B. Benefit of adding low molecular weight heparin to the conventional treatment of stable angina pectoris. A double-blind, randomized, placebo-controlled trial. Circulation. 1993 Dec;88(6):2517–2523. doi: 10.1161/01.cir.88.6.2517. [DOI] [PubMed] [Google Scholar]
  28. Nakagawa S., Hanada Y., Koiwaya Y., Tanaka K. Angiographic features in the infarct-related artery after intracoronary urokinase followed by prolonged anticoagulation. Role of ruptured atheromatous plaque and adherent thrombus in acute myocardial infarction in vivo. Circulation. 1988 Dec;78(6):1335–1344. doi: 10.1161/01.cir.78.6.1335. [DOI] [PubMed] [Google Scholar]
  29. Quyyumi A. A., Diodati J. G., Lakatos E., Bonow R. O., Epstein S. E. Angiogenic effects of low molecular weight heparin in patients with stable coronary artery disease: a pilot study. J Am Coll Cardiol. 1993 Sep;22(3):635–641. doi: 10.1016/0735-1097(93)90169-2. [DOI] [PubMed] [Google Scholar]
  30. Ranke C., Hecker H., Creutzig A., Alexander K. Dose-dependent effect of aspirin on carotid atherosclerosis. Circulation. 1993 Jun;87(6):1873–1879. doi: 10.1161/01.cir.87.6.1873. [DOI] [PubMed] [Google Scholar]
  31. Schneidau A., Harrison M. J., Hurst C., Wilkes H. C., Meade T. W. Arterial disease risk factors and angiographic evidence of atheroma of the carotid artery. Stroke. 1989 Nov;20(11):1466–1471. doi: 10.1161/01.str.20.11.1466. [DOI] [PubMed] [Google Scholar]
  32. Schoebel F. C., Leschke M., Jax T. W., Stein D., Strauer B. E. Chronic-intermittent urokinase therapy in patients with end-stage coronary artery disease and refractory angina pectoris--a pilot study. Clin Cardiol. 1996 Feb;19(2):115–120. doi: 10.1002/clc.4960190209. [DOI] [PubMed] [Google Scholar]
  33. Schuff-Werner P., Gohlke H., Bartmann U., Baggio G., Corti M. C., Dinsenbacher A., Eisenhauer T., Grützmacher P., Keller C., Kettner U. The HELP-LDL-apheresis multicentre study, an angiographically assessed trial on the role of LDL-apheresis in the secondary prevention of coronary heart disease. II. Final evaluation of the effect of regular treatment on LDL-cholesterol plasma concentrations and the course of coronary heart disease. The HELP-Study Group. Heparin-induced extra-corporeal LDL-precipitation. Eur J Clin Invest. 1994 Nov;24(11):724–732. doi: 10.1111/j.1365-2362.1994.tb01068.x. [DOI] [PubMed] [Google Scholar]
  34. Seidel D., Armstrong V. W., Schuff-Werner P. The HELP-LDL-apheresis multicentre study, an angiographically assessed trial on the role of LDL-apheresis in the secondary prevention of coronary heart disease. I. Evaluation of safety and cholesterol-lowering effects during the first 12 months. HELP Study Group. Eur J Clin Invest. 1991 Aug;21(4):375–383. doi: 10.1111/j.1365-2362.1991.tb01384.x. [DOI] [PubMed] [Google Scholar]
  35. Smith E. B., Alexander K. M., Massie I. B. Insoluble "fibrin" in human aortic intima. Quantitative studies on the relationship between insoluble "fibrin", soluble fibrinogen and low density lipoprotein. Atherosclerosis. 1976 Jan-Feb;23(1):19–39. doi: 10.1016/0021-9150(76)90116-7. [DOI] [PubMed] [Google Scholar]
  36. Smith E. B., Keen G. A., Grant A., Stirk C. Fate of fibrinogen in human arterial intima. Arteriosclerosis. 1990 Mar-Apr;10(2):263–275. doi: 10.1161/01.atv.10.2.263. [DOI] [PubMed] [Google Scholar]
  37. Thompson S. G., Kienast J., Pyke S. D., Haverkate F., van de Loo J. C. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med. 1995 Mar 9;332(10):635–641. doi: 10.1056/NEJM199503093321003. [DOI] [PubMed] [Google Scholar]
  38. Treasure C. B., Klein J. L., Weintraub W. S., Talley J. D., Stillabower M. E., Kosinski A. S., Zhang J., Boccuzzi S. J., Cedarholm J. C., Alexander R. W. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med. 1995 Feb 23;332(8):481–487. doi: 10.1056/NEJM199502233320801. [DOI] [PubMed] [Google Scholar]
  39. Wolf R., Lichtlen P. R. Die Beziehung zwischen Plasmafibrinogen und der Funktion koronarer Kollateralgefässe. Z Kardiol. 1995 May;84(5):348–359. [PubMed] [Google Scholar]

Articles from Heart are provided here courtesy of BMJ Publishing Group

RESOURCES